{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:02:42Z","timestamp":1785402162135,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2022 EKEA.21"],"award-info":[{"award-number":["2022 EKEA.21"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2022 EKEA.21"],"award-info":[{"award-number":["2022 EKEA.21"]}],"id":[{"id":"https:\/\/ror.org\/03zcxha54","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Homburger Forschungsf\u00f6rderungsprogramm"},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"crossref","award":["NIH P30 CA008748"],"award-info":[{"award-number":["NIH P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"crossref"}]},{"award":["NIH P30 CA008748"],"award-info":[{"award-number":["NIH P30 CA008748"]}],"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The role of immune checkpoint inhibition in treating head and neck squamous cell carcinoma (HNSCC) is expanding, yet response rates to PD-L1 therapy remain inconsistent and generally poor. Although several studies have examined heterogeneous intratumoral PD-L1 expression, the disparity in response to PD-L1 therapy between primary tumors and their associated lymph node metastases remains unclear. Methods: Primary tumor samples and two matching lymph node metastases were obtained from a cohort of 50 patients and immunohistochemically stained with a PD-L1 antibody. PD-L1 expression, assessed using the combined positive score (CPS) and tumor proportion score (TPS), and immune infiltration, measured with an immunoreactive score (IRS), were compared between the primary tumor and lymph node metastases. These measures were then correlated with other histopathological and clinical features. Results: PD-L1 expression, evaluated by CPS and TPS, showed no significant differences between the primary tumor and matched lymph node metastases. Discordance relative to established regulatory cut-offs was observed in a subset of patients, affecting 18% (CPS; 95% CI, 8.0\u201330.0%) and 4% (TPS; 95% CI, 0.0\u201310.0%) of cases. CPS and TPS values were not influenced by primary tumor subsite or HPV status. Conversely, immune infiltration measured by IRS was significantly affected by primary tumor subsite location. Both HPV tumor status and primary tumor subsite were statistically significantly associated with overall survival. Conclusions: Our findings highlight variability in PD-L1 expression in HNSCC and may offer context for differential responses of primary tumors and lymph node metastases to immune checkpoint therapy reported in recent clinical studies. These observations support the need for a more comprehensive characterization of PD-L1 expression across tumor sites in head and neck cancer. Further investigation is required to determine whether, and in which settings, reassessment of PD-L1 status in metastatic lesions\u2014including lymph node metastases\u2014may provide additional clinically relevant information when initial testing does not meet established therapeutic cut-offs.<\/jats:p>","DOI":"10.3390\/cancers18081286","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:15:08Z","timestamp":1776669308000},"page":"1286","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5996-6657","authenticated-orcid":false,"given":"Moritz","family":"Knebel","sequence":"first","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert Georg","family":"Klamminger","sequence":"additional","affiliation":[{"name":"Department of General and Surgical Pathology, Saarland University Medical Center, 66421 Homburg, Germany"},{"name":"Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-2940","authenticated-orcid":false,"given":"Sandrina","family":"K\u00f6rner","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-5188","authenticated-orcid":false,"given":"Silke","family":"Wemmert","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6961-8510","authenticated-orcid":false,"given":"Lukas Alexander","family":"Brust","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Braun","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-6545","authenticated-orcid":false,"given":"Sigrun","family":"Smola","sequence":"additional","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany"},{"name":"Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 66123 Saarbr\u00fccken, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of General and Surgical Pathology, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ertz","sequence":"additional","affiliation":[{"name":"Department of General and Surgical Pathology, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-2280","authenticated-orcid":false,"given":"Luc G. T.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA"},{"name":"Laboratory of Experimental Cancer Immunogenomics, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schick","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-9282","authenticated-orcid":false,"given":"Maximilian","family":"Linxweiler","sequence":"additional","affiliation":[{"name":"Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Barsouk, A., Aluru, J.S., Rawla, P., Saginala, K., and Barsouk, A. (2023). Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med. Sci., 11.","DOI":"10.3390\/medsci11020042"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","article-title":"Human papillomavirus as a driver of head and neck cancers","volume":"122","author":"Sabatini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Economopoulou, P., Kotsantis, I., and Psyrri, A. (2020). Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. Cancers, 12.","DOI":"10.3390\/cancers12113377"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meliante, P.G., Zoccali, F., de Vincentiis, M., Ralli, M., Petrella, C., Fiore, M., Minni, A., and Barbato, C. (2023). Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. Diagnostics, 13.","DOI":"10.3390\/diagnostics13050862"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101977","DOI":"10.1016\/j.ctrv.2020.101977","article-title":"Biomarkers for immunotherapy response in head and neck cancer","volume":"84","author":"Gavrielatou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41416-019-0449-y","article-title":"Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma","volume":"120","author":"Rasmussen","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000515441","article-title":"Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma","volume":"99","author":"Hirshoren","year":"2021","journal-title":"Oncology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"Der pr\u00e4diktive Wert der PD-L1-Diagnostik","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Der Pathol."},{"key":"ref_16","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"K\u00fchn, J.P., Schmid, W., K\u00f6rner, S., Bochen, F., Wemmert, S., Rimbach, H., Smola, S., Radosa, J.C., Wagner, M., and Morris, L.G.T. (2021). HPV Status as Prognostic Biomarker in Head and Neck Cancer-Which Method Fits the Best for Outcome Prediction?. Cancers, 13.","DOI":"10.3390\/cancers13184730"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): A multicentre, multinational, individual patient data analysis","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1099\/0022-1317-76-4-1057","article-title":"The use of general primers GP5 and GP6 elongated at their 3\u2032 ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR","volume":"76","author":"Walboomers","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1128\/JVI.01016-08","article-title":"Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21","volume":"82","author":"Ruprecht","year":"2008","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Qiao, X.W., Jiang, J., Pang, X., Huang, M.C., Tang, Y.J., Liang, X.H., and Tang, Y.L. (2020). The Evolving Landscape of PD-1\/PD-L1 Pathway in Head and Neck Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01721"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e14502","DOI":"10.1200\/JCO.2017.35.15_suppl.e14502","article-title":"Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00405-022-07775-z","article-title":"Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma","volume":"280","author":"Schmidl","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/his.13646","article-title":"PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis\u2013impact on clinical outcome","volume":"73","author":"Schneider","year":"2018","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Deuss, E., K\u00fcrten, C., Fehr, L., Kahl, L., Zimmer, S., K\u00fcnzel, J., Stauber, R.H., Lang, S., Hussain, T., and Brandau, S. (2024). Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications. Cancers, 16.","DOI":"10.3390\/cancers16112103"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00428-022-03322-7","article-title":"PD-L1 expression in head and neck carcinoma by combined positive score: A comparison among preoperative biopsy, tumor resection, and lymph node metastasis","volume":"481","author":"Limarzi","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hampton, H.R., and Chtanova, T. (2019). Lymphatic Migration of Immune Cells. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01168"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5858\/arpa.2021-0464-OA","article-title":"Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma","volume":"147","author":"Kaur","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104719","DOI":"10.1016\/j.oraloncology.2020.104719","article-title":"Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma","volume":"106","author":"Brcic","year":"2020","journal-title":"Oral. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41467-023-37379-y","article-title":"Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis","volume":"14","author":"Quah","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_31","first-page":"107","article-title":"Role of HPV status and PD-L1 expression in prognosis of laryngeal squamous cell carcinoma","volume":"14","author":"Yang","year":"2021","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, B. (2023). Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches. Critical Issues in Head and Neck Oncology, Springer.","DOI":"10.1007\/978-3-031-23175-9_6"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.5114\/ada.2021.112274","article-title":"PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: A review","volume":"38","author":"Adamczyk","year":"2021","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7150\/jca.27199","article-title":"PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection","volume":"10","author":"Lyu","year":"2019","journal-title":"J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chu, C., Yao, K., Lu, J., Zhang, Y., Chen, K., Lu, J., Zhang, C.Z., and Cao, Y. (2020). Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification. Cancers, 12.","DOI":"10.3390\/cancers12071796"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"FSO768","DOI":"10.2144\/fsoa-2021-0039","article-title":"Increased PD-L1 and p16 Expression are Common in Oropharyngeal Squamous Cell Carcinoma","volume":"7","author":"Shestakova","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.3390\/curroncol29060334","article-title":"Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma","volume":"29","author":"Park","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.02.008","article-title":"Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians","volume":"65","author":"Alt","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.09.016","article-title":"The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis","volume":"86","author":"Yang","year":"2018","journal-title":"Oral. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12967-019-02182-1","article-title":"SUPREME-HN: A retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"17","author":"Pai","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.21873\/anticanres.14394","article-title":"Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma","volume":"40","author":"Jeong","year":"2020","journal-title":"Anticancer. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.radonc.2018.08.023","article-title":"Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma","volume":"129","author":"Fukushima","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wuerdemann, N., G\u00fcltekin, S.E., P\u00fctz, K., Wittekindt, C., Huebbers, C.U., Sharma, S.J., Eckel, H., Schubotz, A.B., Gattenl\u00f6hner, S., and B\u00fcttner, R. (2020). PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155228"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.18632\/oncotarget.7593","article-title":"CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity","volume":"7","author":"Straub","year":"2016","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104722","DOI":"10.1016\/j.oraloncology.2020.104722","article-title":"Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis","volume":"106","author":"Lenouvel","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Merlino, D.J., Johnson, J.M., Tuluc, M., Gargano, S., Stapp, R., Harshyne, L., Leiby, B.E., Flanders, A., Zinner, R., and Axelrod, R. (2020). Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.566315"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1016\/j.annonc.2022.07.794","article-title":"670P Discordant pathologic tumor response in primary tumors and lymph nodes after neoadjuvant immune checkpoint inhibition (ICI) in head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Luginbuhl","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1286\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:17:16Z","timestamp":1776745036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081286"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081286","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]}}}